Physician profile
Robert Jones
NPI 1144859307
$1,701.33
in general payments reported to CMS, 2019-2025
17 companies · $799 in 2025
The $799 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $144 · 2024: $758 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,701.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $457.84 | 2023-2025 | |
| Glaxosmithkline, LLC. | $251.38 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Lilly USA, LLC | $209.30 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Exact Sciences Corporation | $154.89 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $128.25 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $120.30 | 2024-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Novo Nordisk INC | $68.22 | 2024-2025 | Ozempic, Rybelsus |
| Seqirus USA INC | $64.15 | 2023-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Astrazeneca Pharmaceuticals LP | $60.44 | 2024-2025 | Farxiga |
| Astellas Pharma US INC | $40.80 | 2024-2025 | Veozah |
| Inspire Medical Systems, INC. | $27.03 | 2024 | Inspire |
| Janssen Pharmaceuticals, INC | $25.71 | 2024 | Spravato |
| Ultragenyx Pharmaceutical INC. | $24.40 | 2025 | Crysvita |
| Organon LLC | $23.04 | 2025 | Nexplanon |
| Corcept Therapeutics | $21.05 | 2025 | Korlym |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $14.28 | 2024 | Venaseal |
| Phathom Pharmaceuticals, INC. | $10.25 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.